AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
In vitro-based potency assay for anthrax vaccine developed.
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- Scientists have developed an in vitro-based potency assay for anthrax vaccines.
According to recent research published in the journal Vaccine, "The potency assay currently used to evaluate consistency of manufacture for the anthrax vaccine is contingent upon meeting specified parameters after statistical analysis of the percent survival and time to death of vaccinated guinea pigs after challenge with spores of a virulent strain of Bacillus anthracis."
"During the development of a new anthrax vaccine based upon recombinant protective antigen (rPA) adsorbed to aluminum hydroxide gel (Alhydrogel), we found that the serological response of female A/J mice, as measured by a quantitative anti-rPA IgG ELISA, may be an effective method to monitor a manufacturer's consistency for rPA-based vaccines," said Stephen F. Little and colleagues at the U.S. Army Medical Research Institute of Infectious Diseases. "An advantage of the proposed in vitro-based potency assay is ...
- VaxGen, Inc: Next Clinical Trial of VaxGen's Anthrax Vaccine Delayed - Final.
- News wire article from: Fair Disclosure Wire November 3, 2006 700+ words
...EVP, TEAM LEADER-ANTHRAX VACCINE PROJECT, VAXGEN...Phase II trial of its anthrax vaccine candidate. In order...case, the proposed anthrax vaccine, is and will remain...sensitive in vivo potency assay. As with all in...
- Deducing in vivo toxicity of combustion-derived nanoparticles from a cell-free...
- Magazine article from: Environmental Health Perspectives Stoeger, Tobias Takenaka, Shinji Frankenberger, Birgit Ritter, Baerbel Karg, Erwin Maier, Konrad Schulz, Holger Schmid, Otmar January 1, 2009 700+ words
BACKGROUND: The inhalation of combustion-derived nanoparticles (CDNPs) is believed to cause an oxidative stress response, which in turn may lead to pulmonatry or even systemic inflammation. OBJECTIVE AND METHODS: In this study we assessed whether the in vivo inflammatory response--which is
- VaxGen Awarded $80.3 Million NIAID Contract for Advanced Development of Anthrax...
- Press release article from: PR Newswire October 1, 2003 700+ words
...for the advanced development of its anthrax vaccine candidate, rPA102. The 3-year...contract for a national stockpile of anthrax vaccine. (Logo: http://www.newscom...recombinant Protective Antigen (rPA) anthrax vaccine, pending legislation known as Project...
- VaxGen Completes Development Activity in Support of Anthrax Vaccine Partnering...
- Press release article from: PR Newswire May 24, 2007 700+ words
...further development of its recombinant anthrax vaccine and is laying off 20 employees, or...support ongoing efforts to partner its anthrax vaccine program and was based on the Department...procurement of a next-generation anthrax vaccine. (Logo: NewsCom: http://www...
- Citizen Petition Filed Yesterday at the FDA: Anthrax Vaccine Network Supports...
- Press release article from: PR Newswire October 16, 2001 700+ words
...Michigan firm which manufactures the anthrax vaccine. The petition calls for the FDA to...on the drug category placement of anthrax vaccine as Category II (unsafe, ineffective...declare as adulterated all stockpiles of anthrax vaccine adsorbed in the possession of BioPort...
- VaxGen Responds to Media Report Regarding Proposed Congressional Investigation...
- Press release article from: PR Newswire April 6, 2006 700+ words
...investigation into the company's anthrax vaccine contract by Congressman Mike Rogers...investigation of our Project BioShield anthrax vaccine contract, because: -- The Department...contract for 75 million doses of a modern anthrax vaccine to VaxGen was the result of an open...
- Anthrax Vaccine Award Rescheduled to Nov. 5; VaxGen Believes It Is the Only...
- Press release article from: PR Newswire October 15, 2004 700+ words
...million doses of a recombinant anthrax vaccine to the U.S. government...VaxGen has been developing its anthrax vaccine candidate, rPA102, to address...for a modern recombinant anthrax vaccine, based on a single defined...
- Dynavax Anthrax Vaccine Induces High Antibody Responses and Shows Protection in...
- Press release article from: PR Newswire March 21, 2005 700+ words
...immunostimulatory sequence (ISS) based anthrax vaccine has the potential to confer...to the currently available anthrax vaccine and a prototype second-generation...Our novel, proprietary anthrax vaccine formulation has potential...
- Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax...
- Press release article from: Business Wire May 5, 2008 700+ words
...a domestic source for an advanced anthrax vaccine candidate to meet planned procurement...recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology...procure 25 million doses of an rPA anthrax vaccine for the Strategic National Stockpile...
- VaxGen and BD to Jointly Evaluate Novel Dermal Injection Technology for...
- Press release article from: PR Newswire February 21, 2006 700+ words
...to deliver VaxGen's recombinant anthrax vaccine candidate. Funding will be provided...injection into the skin) of VaxGen's anthrax vaccine with the patented BD Micro Injection...technology in combination with VaxGen's anthrax vaccine proves safe and effective, and is...
Source: HighBeam Research, In vitro-based potency assay for anthrax vaccine developed.